TP53 Mutations Promote Immunogenic Activity in Breast Cancer

BACKGROUND: Although immunotherapy has recently achieved clinical successes in a variety of cancers, thus far there is no immunotherapeutic strategy for breast cancer (BC). Thus, it is important to discover biomarkers for identifying BC patients responsive to immunotherapy. TP53 mutations were often...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Zhixian, Jiang, Zehang, Gao, Yingsheng, Wang, Lirui, Chen, Cai, Wang, Xiaosheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582869/
https://www.ncbi.nlm.nih.gov/pubmed/31275382
http://dx.doi.org/10.1155/2019/5952836

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6582869/
https://www.ncbi.nlm.nih.gov/pubmed/31275382
http://dx.doi.org/10.1155/2019/5952836

Ejemplares similares